Regeneron Pharmaceuticals REGN underwent analysis by 16 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 7 | 4 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 3 | 1 | 2 | 1 | 0 |
| 2M Ago | 1 | 3 | 0 | 0 | 0 |
| 3M Ago | 0 | 3 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $1046.81, a high estimate of $1189.00, and a low estimate of $720.00. This current average has increased by 1.92% from the previous average price target of $1027.10.
Investigating Analyst Ratings: An Elaborate Study
The analysis of recent analyst actions sheds light on the perception of Regeneron Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $925.00 | - |
| Tyler Van Buren | TD Cowen | Raises | Buy | $1030.00 | $1020.00 |
| Colin Bristow | UBS | Raises | Buy | $1099.00 | $1090.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Neutral | $925.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Neutral | $925.00 | - |
| Geoff Meacham | B of A Securities | Raises | Underperform | $720.00 | $710.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $1189.00 | - |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $1135.00 | $1135.00 |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $1135.00 | $1135.00 |
| Matthew Harrison | Morgan Stanley | Raises | Overweight | $1115.00 | $1104.00 |
| William Pickering | Bernstein | Announces | Outperform | $1125.00 | - |
| Aaron Gal | Bernstein | Announces | Outperform | $1125.00 | - |
| Brian Abrahams | RBC Capital | Raises | Outperform | $1184.00 | $1096.00 |
| Olivia Brayer | Cantor Fitzgerald | Raises | Neutral | $925.00 | $850.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $1110.00 | $1076.00 |
| Evan David Seigerman | BMO Capital | Raises | Outperform | $1082.00 | $1055.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Regeneron Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Regeneron Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Regeneron Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Regeneron Pharmaceuticals analyst ratings.
All You Need to Know About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Financial Milestones: Regeneron Pharmaceuticals's Journey
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Regeneron Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 0.58%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Regeneron Pharmaceuticals's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 33.77%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.56%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 3.55%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.1, Regeneron Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: Simplified
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
